1,598 results match your criteria HIV Medicine[Journal]


Long-term loss to follow-up in the TREAT Asia HIV Observational Database (TAHOD).

HIV Med 2019 Apr 12. Epub 2019 Apr 12.

Faculty of Medicine, Udayana University & Sanglah Hospital, Bali, Indonesia.

Objectives: With earlier antiretroviral therapy (ART) initiation, time spent in HIV care is expected to increase. We aimed to investigate loss to follow-up (LTFU) in Asian patients who remained in care 5 years after ART initiation.

Methods: Long-term LTFU was defined as LTFU occurring after 5 years on ART. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/hiv.12734
Publisher Site
http://dx.doi.org/10.1111/hiv.12734DOI Listing
April 2019
2 Reads
3.988 Impact Factor

Renal dysfunction by baseline CD4 cell count in a cohort of adults starting antiretroviral treatment regardless of CD4 count in the HIV Prevention Trials Network 071 [HPTN 071; Population Effect of Antiretroviral Therapy to Reduce HIV Transmission (PopART)] study in South Africa.

HIV Med 2019 Apr 8. Epub 2019 Apr 8.

Department of Medicine, Imperial College London, London, UK.

Objectives: Renal dysfunction is a significant cause of morbidity and mortality among HIV-positive individuals. This study evaluated renal dysfunction in a cohort of adults who started antiretroviral treatment (ART) regardless of CD4 count at three Department of Health (DOH) clinics included in the HIV Prevention Trials Network 071 (HPTN 071) Population Effect of Antiretroviral Therapy to Reduce HIV Transmission (PopART) trial.

Methods: A retrospective cohort analysis of routine data for HIV-positive individuals starting ART between January 2014 and November 2015 was completed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12729DOI Listing
April 2019
1 Read

Routine screening for HIV, hepatitis B virus and hepatitis C virus in individuals undergoing oral and maxillofacial surgery.

HIV Med 2019 May 29;20(5):353-358. Epub 2019 Mar 29.

Service de Maladies Infectieuses, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France.

Objectives: Given the effectiveness of treatment of HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, there are considerable benefits associated with determining HIV/HBV/HCV status. We evaluated the feasibility and acceptability of systematic screening and subsequent care in an oral and maxillofacial surgery department.

Methods: The anaesthesiologists proposed screening for HIV, HBV and HCV to all individuals of unknown infection status undergoing surgery between 19 April 2016 and 19 April 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12732DOI Listing
May 2019
2 Reads

Rebuttal: Response to the comments by Buck et al. on our published article: Hepatic and renal toxicity and associated factors among HIV-infected children on antiretroviral therapy: a prospective cohort study; HIV Medicine (2019), 20, 147-156.

HIV Med 2019 Mar 29. Epub 2019 Mar 29.

Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12742DOI Listing

Immediate treatment of acute HIV in a tertiary healthcare center: bridging gaps in communication using smartphones.

HIV Med 2019 May 29;20(5):308-316. Epub 2019 Mar 29.

Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Tlalpan, Mexico City, México.

Objectives: Early initiation of antiretroviral therapy (ART) during acute HIV infection is associated with favourable clinical and epidemiological outcomes. Barriers to prompt treatment initiation limit the benefits of universal access to ART in Mexico. We sought to create an algorithm for the immediate detection and treatment of patients with acute HIV infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12713DOI Listing

Use of dabigatran with antiretrovirals.

HIV Med 2019 May 29;20(5):344-346. Epub 2019 Mar 29.

St Vincent's Hospital, Sydney, NSW, Australia.

Objectives: Theoretical and untested interactions between antiretrovirals and direct-acting oral anticoagulants have limited the use of this new class of anticoagulant in people with HIV infection. This case series, the first of its kind, reports on the successful concurrent use of the direct-acting oral anticoagulant dabigatran and antiretroviral therapy.

Methods: This series involved 14 patients requiring anticoagulation for management of atrial fibrillation, who were either unable or unwilling to take warfarin, and who were receiving concurrent treatment for HIV infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12722DOI Listing

Depression and all-cause mortality risk in HIV-infected and HIV-uninfected US veterans: a cohort study.

HIV Med 2019 May 29;20(5):317-329. Epub 2019 Mar 29.

VA Tennessee Valley Healthcare System, Vanderbilt University School of Medicine, Nashville, TN, USA.

Objectives: The contribution of depression to mortality in adults with and without HIV infection is unclear. We hypothesized that depression increases mortality risk and that this association is stronger among those with HIV infection.

Methods: Veterans Aging Cohort Study (VACS) data were analysed from the first clinic visit on or after 1 April 2003 (baseline) to 30 September 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12726DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459698PMC

Missed opportunities to prevent mother-to-child transmission of HIV in Italy.

HIV Med 2019 May 29;20(5):330-336. Epub 2019 Mar 29.

Department of Health Sciences, University of Florence, Meyer Children's Hospital, Florence, Italy.

Objectives: Vertical transmission of HIV can be effectively controlled through antenatal screening, antiretroviral treatment and the services provided during and after childbirth for mother and newborn. In Italy, the National Health Service guarantees universal access to prenatal care for all women, including women with HIV infection. Despite this, children are diagnosed with HIV infection every year. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12728DOI Listing
May 2019
2 Reads

Secondary adrenal insufficiency from steroid use and co-prescribing of cytochrome p450 3A4 inhibitors.

HIV Med 2019 May 29;20(5):e10-e11. Epub 2019 Mar 29.

Brighton & Sussex University Hospitals NHS Trust, Brighton, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12723DOI Listing
May 2019
3 Reads

Level of agreement between frequently used cardiovascular risk calculators in people living with HIV.

HIV Med 2019 May 14;20(5):347-352. Epub 2019 Mar 14.

Section of Retrovirology, Department of Medicine, St Mary's Hospital Campus, Imperial College London, London, UK.

Objectives: The aim of the study was to describe agreement between the QRISK2, Framingham and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) cardiovascular disease (CVD) risk calculators in a large UK study of people living with HIV (PLWH).

Methods: PLWH enrolled in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) study without a prior CVD event were included in this study. QRISK2, Framingham CVD and the full and reduced D:A:D CVD scores were calculated; participants were stratified into 'low' (< 10%), 'intermediate' (10-20%) and 'high' (> 20%) categories for each. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12731DOI Listing
May 2019
2 Reads

Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen.

HIV Med 2019 May 14;20(5):337-343. Epub 2019 Mar 14.

Janssen Research & Development, LLC, Titusville, NJ, USA.

Objectives: The aim of the study was to evaluate darunavir and cobicistat pharmacokinetics in pregnant women with HIV-1 infection.

Methods: This phase 3b, open-label study enrolled HIV-1-infected pregnant women (18-26 weeks of gestation) receiving combination antiretroviral therapy with once-daily darunavir/cobicistat 800/150 mg. The plasma pharmacokinetics of darunavir (total and unbound) and cobicistat were assessed over 24 h during the second and third trimesters (24-28 and 34-38 weeks of gestation, respectively) and 6-12 weeks postpartum. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/hiv.12721
Publisher Site
http://dx.doi.org/10.1111/hiv.12721DOI Listing
May 2019
4 Reads

Sexually transmitted infection testing and rates in men who have sex with men (MSM) using HIV pre-exposure prophylaxis.

HIV Med 2019 Mar 14. Epub 2019 Mar 14.

Brighton & Sussex University Hospitals NHS Trust, Brighton, UK.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/hiv.12736
Publisher Site
http://dx.doi.org/10.1111/hiv.12736DOI Listing
March 2019
2 Reads

BHIVA/BASHH guidelines on the use of HIV pre-exposure prophylaxis (PrEP) 2018.

Authors:

HIV Med 2019 Mar;20 Suppl 2:s2-s80

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12718DOI Listing
March 2019
6 Reads

Severe haematologic toxicity is rare in high risk HIV-exposed infants receiving combination neonatal prophylaxis.

Authors:

HIV Med 2019 May 7;20(5):291-307. Epub 2019 Mar 7.

Objectives: Combination neonatal prophylaxis (CNP) is recommended in high-risk situations for the prevention of mother-to-child HIV transmission, although data on its safety are limited. The aim of the study was to identify whether neonatal prophylaxis (NP) type is associated with the risk of severe anaemia or neutropaenia.

Methods: An individual patient data meta-analysis was conducted within six European cohorts, in infants at high risk for acquiring HIV infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12696DOI Listing
May 2019
6 Reads

Two-drug vs. three-drug combinations for HIV-1: Do we have enough data to make the switch?

HIV Med 2019 Apr;20 Suppl 4:2-12

Department of Infectious Diseases, Liege University Hospital, University of Liege, Liège, Belgium.

Three-drug combination antiretroviral therapy (ART) became available in 1996, dramatically improving the prognosis of people living with HIV. The clinical benefits of ART are due to the sustained viral load suppression and CD4 T cell gains. Major drawbacks of the first ART regimens were adverse events, and high pill burden, which led to the reduction of drug adherence resulting in frequent treatment discontinuations and the development of drug resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12716DOI Listing
April 2019
3 Reads

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA.

HIV Med 2019 Apr 8;20(4):264-273. Epub 2019 Feb 8.

Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, UK.

Objectives: The aim of the study was to establish a methodology for evaluating the hepatitis C continuum of care in HIV/hepatitis C virus (HCV)-coinfected individuals and to characterize the continuum in Europe on 1 January 2015, prior to widespread access to direct-acting antiviral (DAA) therapy.

Methods: Stages included in the continuum were as follows: anti-HCV antibody positive, HCV RNA tested, currently HCV RNA positive, ever HCV RNA positive, ever received HCV treatment, completed HCV treatment, follow-up HCV RNA test, and cure. Sustained virological response (SVR) could only be assessed for those with a follow-up HCV RNA test and was defined as a negative HCV RNA result measured > 12 or 24 weeks after stopping treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12711DOI Listing
April 2019
2 Reads

Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV-negative controls.

HIV Med 2019 Apr 8;20(4):274-285. Epub 2019 Feb 8.

Division of Infectious Diseases, Imperial College London, London, UK.

Objectives: We investigated whether differences in cognitive performance between people living with HIV (PLWH) and comparable HIV-negative people were mediated or moderated by depressive symptoms and lifestyle factors.

Methods: A cross-sectional study of 637 'older' PLWH aged ≥ 50 years, 340 'younger' PLWH aged < 50 years and 276 demographically matched HIV-negative controls aged ≥ 50 years enrolled in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) study was performed. Cognitive function was assessed using a computerized battery (CogState). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12714DOI Listing

Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps.

HIV Med 2019 Mar;20 Suppl 1:3-11

Hospital Clinico San Carlos, Universidad Complutense, Madrid, Spain.

Initiating antiretroviral therapy (ART) as early as the day of HIV diagnosis is a strategy of increasing global interest to control the HIV epidemic and optimize the health of people living with HIV (PLWH). No detrimental effects of rapid-start ART have been identified in randomized controlled trials undertaken in low- or middle-income countries, or in cohort studies performed in high-income countries. Rapid-start ART may be a key approach in reaching the 2020 Joint United Nations Programme on HIV/AIDS goal of 90% of all PLWH knowing their status, 90% of those diagnosed receiving sustained ART, and 90% of those receiving ART achieving viral suppression; it may also be important for achieving the suggested fourth "90%" goal: improving health-related quality-of-life in PLWH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12708DOI Listing
March 2019
3 Reads

Implementing screening, brief intervention and referral to treatment in a French cohort of people living with HIV: a pilot study.

HIV Med 2019 Apr 31;20(4):286-290. Epub 2019 Jan 31.

Pathogenesis and Control of Chronic Infections, Montpellier University, INSERM UMR1058, CHU Montpellier, Montpellier, France.

Objectives: Screening, brief intervention and referral to treatment (SBIRT) is an evidence-based practice used to identify, reduce and prevent problematic use and abuse of, and dependence on, tobacco, alcohol and psychoactive substances. To date, the pertinence of this practice among people living with HIV (PLHIV) is unknown. In this pilot study, we aimed to assess the acceptability of SBIRT in a cohort of HIV-infected out-patients who were asked about their consumption of alcohol, tobacco and psychoactive substances. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12709DOI Listing
April 2019
1 Read

A case for reduced frequency of CD4 count monitoring for children on combination antiretroviral therapy with consistently undetectable HIV viral load.

HIV Med 2019 Apr 28;20(4):e8-e9. Epub 2019 Jan 28.

Department of Paediatric Infectious Diseases, Great Ormond Street Hospital for Children NHS Trust, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12706DOI Listing
April 2019
1 Read

Invasive cervical cancer in HIV-infected women: risk and survival relative to those of the general population in France. Results from the French Hospital Database on HIV (FHDH)-Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) CO4 cohort study.

HIV Med 2019 Mar 28;20(3):222-229. Epub 2019 Jan 28.

Sorbonne University, INSERM, IPLESP (Pierre Louis Institute of Public Health), Paris, France.

Objectives: We examined trends in the incidence rates of invasive cervical cancer (ICC) and in the rate of survival after ICC among women living with HIV (WLHIV) in France and compared them to those of the general population.

Methods: Histologically validated incident cases of ICC in the period 1992-2009 from the French Hospital Database on HIV (FHDH-ANRS CO4) were included in the study. Age-standardized incidence rates were estimated for FHDH and the general population in France for 1992-1996 [pre-combination antiretroviral therapy (cART) period], 1997-2000 (early cART period), 2001-2004 (intermediate cART period), and 2005-2009 (late cART period). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12703DOI Listing
March 2019
5 Reads

HIV coinfection among persons diagnosed with hepatitis B in England in 2008-2014.

HIV Med 2019 Apr 28;20(4):255-263. Epub 2019 Jan 28.

National Infection Service, Public Health England, London, UK.

Objectives: The aim of the study was to estimate HIV prevalence among persons with hepatitis B virus (HBV) infection in England and to examine associated risk factors.

Methods: Persons aged ≥ 15 years with an HBV surface antigen (HBsAg) test reported to Public Health England (PHE) sentinel surveillance during 2008-2014 were linked to the PHE national HIV/AIDS database. Coinfection was defined as an HIV diagnosis prior to, or within 6 months following, a positive HBsAg test. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12707DOI Listing
April 2019
8 Reads

Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial.

HIV Med 2019 Mar 27;20(3):202-213. Epub 2019 Jan 27.

Nephrology and Kidney Transplantation Department, Assistance Publique-Hôpitaux de Paris, Institut Francilien de Recherche en Néphrologie et Transplantation, Groupe Hospitalier Henri-Mondor/Albert-Chenevier, Créteil, France.

Objectives: High rates of clinical acute rejection after kidney transplantation have been reported in people living with HIV (PLHIV), probably as a consequence of drug interactions. We therefore investigated the incidence of acute rejection within 6 months of transplantation in HIV-infected recipients treated with a protease-inhibitor-free raltegravir-based regimen.

Methods: The Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE (NCT01453192) study was a prospective multicentre single-arm trial in adult PLHIV awaiting kidney transplantation, with viral load < 50 HIV-1 RNA copies/mL, CD4 T-cell count > 200 cells/μL, and HIV-1 strains sensitive to raltegravir, aiming to demonstrate 6-month clinical acute rejection rates < 30%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12700DOI Listing
March 2019
4 Reads

Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.

HIV Med 2019 Mar 27;20(3):237-247. Epub 2019 Jan 27.

Statistics and Epidemiology, Centre d'Estudis Epidemiològics sobre les ITS i la Sida de Catalunya (CEEISCAT, CIBERESP), Badalona, Spain.

Objectives: The aim of the study was to assess the rates of discontinuation of integrase inhibitor regimens because of any neuropsychiatric adverse event (NPAE) and the factors associated with discontinuation.

Methods: A population-based, prospective, multicentre cohort study was carried out. Treatment-naïve subjects starting therapy with a regimen containing integrase inhibitors, or those switching to such a regimen, with plasma HIV-1 RNA < 50 HIV-1 RNA copies/mL in 14 hospitals in Catalonia or the Balearic Islands (Spain) were included in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12710DOI Listing
March 2019
1 Read

Liver stiffness regression after successful Hepatitis C treatment is independent of HIV coinfection.

HIV Med 2019 Mar 27;20(3):230-236. Epub 2019 Jan 27.

Department of Medicine I, Bonn University Hospital, Bonn, Germany.

Objectives: The aim of the study was to assess the regression of liver stiffness after successful direct-acting antiviral (DAA) treatment in patients with hepatitis C virus (HCV) monoinfection and HCV/-HIV coinfection. In addition, we aimed to identify factors associated with liver stiffness regression.

Methods: We studied patients treated with interferon-free DAA regimens with a sustained virological response at week 12 (SVR ) or 24 (SVR ) post-treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12705DOI Listing
March 2019
2 Reads

Fatal measles as AIDS presentation in Italy.

HIV Med 2019 Mar 22;20(3):e6-e7. Epub 2019 Jan 22.

Department of Sciences for Health Promotion and Mother-Child Care, University of Palermo, Palermo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12704DOI Listing
March 2019
1 Read

De-simplifying single-tablet antiretroviral treatments: uptake, risks and cost savings.

HIV Med 2019 Mar 11;20(3):214-221. Epub 2019 Jan 11.

Southern Alberta Clinic, Calgary, AB, Canada.

Objectives: As more HIV-positive individuals receive antiretroviral therapy (ART), payers are seeking options for covering these increased and sustained drug costs. Strategic use of available generic antiretroviral (ARV) formulations may be feasible. De-simplifying a single-tablet co-formulation (STF) into two or more tablets using both brand and generic drugs has been proposed. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/hiv.12701
Publisher Site
http://dx.doi.org/10.1111/hiv.12701DOI Listing
March 2019
20 Reads

Evaluation of weight-based prescription of antiretroviral therapy in children.

HIV Med 2019 Mar 11;20(3):248-253. Epub 2019 Jan 11.

Biomedical Research and Training Institute, Harare, Zimbabwe.

Objectives: The aim of the study was to investigate the extent of and factors associated with incorrect dosing of antiretroviral therapy (ART) in HIV-infected children in Harare, Zimbabwe.

Methods: All children aged 0-10 years and children aged 11-17 years who weighed < 35 kg and taking ART were recruited from the paediatric HIV clinic at Harare Hospital. Their current doses of ART drugs were compared against doses recommended by the national guidelines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12702DOI Listing
March 2019
4 Reads

Prevalence and predictors of airflow obstruction in an HIV tertiary care clinic in Montreal, Canada: a cross-sectional study.

HIV Med 2019 Mar 8;20(3):192-201. Epub 2019 Jan 8.

Chronic Viral Illness Service/Division of Infectious Diseases, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.

Objectives: The reported prevalence of chronic obstructive pulmonary disease (COPD) in people living with HIV (PLWHIV) varies widely. Our objective was to estimate the prevalence of airflow obstruction and COPD in unselected PLWHIV and identify characteristics that increase the risk of nonreversible airflow obstruction in order to guide case finding strategies for COPD.

Methods: All adults attending the Chronic Viral Illness Service were invited to participate in the study, regardless of smoking status or history of known COPD/asthma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12699DOI Listing
March 2019
2 Reads

Cardiovascular disease-related mortality and factors associated with cardiovascular events in the TREAT Asia HIV Observational Database (TAHOD).

HIV Med 2019 Mar 8;20(3):183-191. Epub 2019 Jan 8.

Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Objectives: With aging of the HIV-positive population, cardiovascular disease (CVD) increasingly contributes to morbidity and mortality. We investigated CVD-related and other causes of death (CODs) and factors associated with CVD in a multi-country Asian HIV-positive cohort.

Methods: Patient data from 2003-2017 were obtained from the Therapeutics, Research, Education and AIDS Training in Asia (TREAT Asia) HIV Observational Database (TAHOD). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/hiv.12687
Publisher Site
http://dx.doi.org/10.1111/hiv.12687DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422532PMC
March 2019
6 Reads
3.988 Impact Factor

Corrigendum.

Authors:

HIV Med 2019 Jan;20(1):74-76

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12698DOI Listing
January 2019
1 Read

Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naïve youth in the HIV Research Network.

HIV Med 2019 Feb 18;20(2):169-174. Epub 2018 Dec 18.

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Objectives: Several single-tablet regimens (STRs) are now available and are recommended for first-line antiretroviral therapy (ART); however, STR use for youth with HIV (YHIV) has not been systematically studied. We examined the characteristics associated with initiation of STRs versus multi-tablet regimens (MTRs) and the virological outcomes for youth with nonperinatally acquired HIV (nPHIV).

Methods: A retrospective cohort study of nPHIV youth aged 13-24 years initiating ART between 2006 and 2014 at 18 US HIV clinical sites in the HIV Research Network was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12695DOI Listing
February 2019
2 Reads

High-risk behaviours, and their associations with mental health, adherence to antiretroviral therapy and HIV parameters, in HIV-positive men who have sex with men.

HIV Med 2019 Feb 12;20(2):131-136. Epub 2018 Dec 12.

University College London, London, UK.

Objectives: To investigate the patterns and frequency of multiple risk behaviours (alcohol, drugs, smoking, higher risk sexual activity) among men who have sex with men (MSM) living with HIV.

Methods: Cross sectional study.

Results: 147 out of 819 HIV-positive MSM exhibited a high-risk phenotype (defined as >3 of smoking, excess alcohol, sexually transmitted infection and recent recreational drug use). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12690DOI Listing
February 2019
2 Reads

Does region of origin influence the timing and outcome of first-line antiretroviral therapy in France?

HIV Med 2019 Feb 3;20(2):175-181. Epub 2018 Dec 3.

Department of Internal Medicine, Antoine Béclère Hospital, Clamart, France.

Objectives: The aim of the study was to assess whether the timing of combination antiretroviral therapy (cART) initiation, the choice of cART and virological response differ in migrants versus European natives in the north and east of Paris area, after dissemination of French recommendations for universal treatment.

Methods: Antiretroviral therapy-naïve HIV-1-infected adults with at least two follow-up visits at one of 15 participating centres between 1 January 2014 and 31 March 2015 were included in the study. Factors associated with cART initiation before 31 March 2015, with protease inhibitor (PI)-containing cART among individuals initiating cART, and with 1-year virological success after cART initiation were assessed using multivariable logistic regression models. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/hiv.12697
Publisher Site
http://dx.doi.org/10.1111/hiv.12697DOI Listing
February 2019
11 Reads

Cardiovascular disease and diabetes in HIV-positive and HIV-negative gay and bisexual men over the age of 55 years in Australia: insights from the Australian Positive & Peers Longevity Evaluation Study.

HIV Med 2019 Feb 26;20(2):121-130. Epub 2018 Nov 26.

The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.

Objectives: As HIV-positive people age, diagnosis and management of comorbidities associated with ageing are of increasing concern. In this study, we aimed to compare the self-reported prevalences of heart disease, stroke, thrombosis and diabetes in older Australian HIV-positive and HIV-negative gay and bisexual men (GBM).

Methods: We analysed data from the Australian Positive & Peers Longevity Evaluation Study (APPLES), a study of a prospectively recruited cross-sectional sample of 228 (51. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12689DOI Listing
February 2019
3 Reads

Lost but not forgotten: A population-based study of mortality and care trajectories among people living with HIV who are lost to follow-up in Ontario, Canada.

HIV Med 2019 Feb 26;20(2):88-98. Epub 2018 Nov 26.

ICES, Toronto, ON, Canada.

Objectives: Selection as a consequence of volunteer participation in, and loss to follow-up from, cohort studies may bias estimates of mortality and other health outcomes. To quantify this potential, we estimated mortality and health service use among people living with HIV (PLWH) who were lost to cohort follow-up (LTCFU) from a volunteer clinical HIV-infected cohort, and compared these to mortality and health service use in active cohort participants and non-cohort-participants living with HIV in Ontario, Canada.

Methods: We analysed population-based provincial health databases from 1995 to 2014, identifying PLWH ≥ 18 years old; these included data from participants in the Ontario HIV Treatment Network Cohort Study (OCS), a volunteer, multi-site clinical HIV-infected cohort. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/hiv.12682
Publisher Site
http://dx.doi.org/10.1111/hiv.12682DOI Listing
February 2019
26 Reads

Hepatic and renal toxicity and associated factors among HIV-infected children on antiretroviral therapy: a prospective cohort study.

HIV Med 2019 Feb 26;20(2):147-156. Epub 2018 Nov 26.

Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.

Objectives: The aim of the study was to investigate the prevalence of renal function and liver enzyme abnormalities among HIV-infected children, changes in prevalence with time on combination antiretroviral therapy (cART), and the factors associated with these abnormalities.

Methods: A prospective cohort study was conducted among HIV-infected children < 18 years old (n = 705) who were on first-line cART. Liver enzymes, renal function, haematology, immunology and virological response were assessed at enrolment and followed bi-annually for 18 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12693DOI Listing
February 2019
5 Reads

Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014.

HIV Med 2019 Feb 21;20(2):99-109. Epub 2018 Nov 21.

University College London, London, UK.

Objectives: The management of HIV disease is complicated by the incidence of a new spectrum of comorbid noncommunicable diseases (NCDs). It is important to document changes in the prevalence of NCDs over time. The aim of the study was to describe the impact of ageing on HIV markers and on the prevalence of NCDs in people living with HIV (PLWHIV) in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) seen for care in 2004-2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12683DOI Listing
February 2019
11 Reads

Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.

HIV Med 2019 Feb 21;20(2):137-146. Epub 2018 Nov 21.

Infectious Diseases Clinic, Policlinico San Martino Hospital, Genoa, Italy.

Objectives: The aim of the study was to analyse the prevalence of integrase resistance mutations in integrase strand transfer inhibitor (INSTI)-experienced HIV-1-infected patients and its predictors.

Methods: We selected HIV-1 integrase sequences from the Antiviral Response Cohort Analysis (ARCA) database, derived from INSTI-experienced patients between 2008 and 2017. Differences in the prevalence of resistance to raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG) were assessed by χ test and predictors of resistance were analysed by logistic regression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12692DOI Listing
February 2019
2 Reads

Inequalities in HIV testing uptake and needs among men who have sex with men living in Ireland: findings from an internet survey.

HIV Med 2019 Feb 20;20(2):157-163. Epub 2018 Nov 20.

Health Protection Surveillance Centre, Dublin, Ireland.

Objectives: HIV disproportionately affects men who have sex with men (MSM) in Ireland. The aim of this study was to improve understanding of HIV testing among MSM living in Ireland to inform prevention and testing initiatives.

Methods: We used data from the MSM Internet Survey Ireland 2015 (MISI 2015), a cross-sectional survey of MSM living in Ireland. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12694DOI Listing
February 2019
8 Reads

Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.

HIV Med 2019 Feb 20;20(2):164-168. Epub 2018 Nov 20.

Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy.

Objectives: The aim of the study was to compare the efficacy and tolerability of switching antiretroviral therapy to dolutegravir + emtricitabine/tenofovir disoproxil fumarate (TDF) with those of switching to elvitegravir/cobicistat/emtricitabine/TDF in clinical practice.

Methods: In a multicentre real-life observational study, we analysed data for HIV-infected patients on antiretroviral treatment with viral load < 50 HIV-1 RNA copies/mL switching to dolutegravir + emtricitabine/TDF (dolutegravir group) or elvitegravir/cobicistat/emtricitabine/TDF (elvitegravir group). Follow-up was censored at 48 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12688DOI Listing
February 2019
13 Reads

Late diagnosis, delayed presentation and late presentation among persons enrolled in a clinical HIV cohort in Ontario, Canada (1999-2013).

HIV Med 2019 Feb 14;20(2):110-120. Epub 2018 Nov 14.

Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Canada.

Objectives: Timely HIV diagnosis and presentation to medical care are important for treatment and prevention. Our objective was to measure late diagnosis, delayed presentation and late presentation among individuals in the Ontario HIV Treatment Network Cohort Study (OCS) who were newly diagnosed in Ontario.

Methods: The OCS is a multi-site clinical cohort study of people living with HIV in Ontario, Canada. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/hiv.12686
Publisher Site
http://dx.doi.org/10.1111/hiv.12686DOI Listing
February 2019
15 Reads

Acute kidney injury in HIV-infected patients: a critical review.

HIV Med 2019 Feb 8;20(2):77-87. Epub 2018 Nov 8.

Division of Nephrology and Renal Transplantation, Department of Medicine, Centro Hospitalar Lisboa Norte, EPE, Lisboa, Portugal.

Acute kidney injury (AKI) is characterized by a rapid decline of renal function associated with worse outcomes. The purpose of the authors is to perform a critical review of the incidence, risk factors, pathogenesis and outcome of AKI in HIV-infected patients. Human immunodeficiency virus (HIV)-infected patients have an increased risk of developing AKI, to which contribute both HIV-dependent and HIV-independent factors as well as the nephrotoxicity of drugs used. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/hiv.12685DOI Listing
February 2019
15 Reads

Risk of neurosyphilis in HIV-infected persons with syphilis lacking signs or symptoms of central nervous system infection.

HIV Med 2019 Jan 7;20(1):27-32. Epub 2018 Nov 7.

Department of Internal Medicine, University of Illinois at Chicago, Chicago, IL, USA.

Objectives: People living with HIV (PLWH) are at increased risk of asymptomatic neurosyphilis; thus, it has been common practice to perform a lumbar puncture (LP) in all PLWH presenting with syphilis regardless of stage, signs or symptoms. However, this practice varies widely among clinicians. Our objective was to elucidate the number of LPs required to diagnose a single case of asymptomatic neurosyphilis. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/hiv.12677
Publisher Site
http://dx.doi.org/10.1111/hiv.12677DOI Listing
January 2019
9 Reads

Shedding light on IRIS: from Pathophysiology to Treatment of Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome in HIV-Infected Individuals.

Authors:
A Balasko Y Keynan

HIV Med 2019 Jan 25;20(1):1-10. Epub 2018 Oct 25.

Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada.

Objectives: The aim of this work was to review current treatment options and propose alternatives for immune reconstitution inflammatory syndrome (IRIS) in HIV-infected individuals with cryptococcal meningitis (CM) (termed 'HIV-CM IRIS'). As a consequence of the immunocompromised state of these individuals, the initial immune response to CM is predominantly type 2 T helper (Th2) /Th17 rather than Th1, leading to inefficient fungal clearance at the time of antiretroviral initiation, and a subsequent overexaggeration of the Th1 response and life-threatening IRIS development.

Methods: An article-based and clinical trial-based search was conducted to investigate HIV-CM IRIS pathophysiology and current treatment practices. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/hiv.12676
Publisher Site
http://dx.doi.org/10.1111/hiv.12676DOI Listing
January 2019
20 Reads

Heterogeneity of virological suppression in the national antiretroviral programme of Cameroon (ANRS 12288 EVOLCAM).

HIV Med 2019 Jan 25;20(1):38-46. Epub 2018 Oct 25.

IRD, INSERM, University of Montpellier, TransVIHMI, Montpellier, France.

Objectives: In terms of HIV infection, western and central Africa is the second most affected region world-wide, and the gap between the regional figures for the testing and treatment cascade and the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets is particularly worrying. We assessed the prevalence of virological suppression in patients routinely treated in 19 hospitals in Cameroon.

Methods: A cross-sectional survey was performed in adult patients receiving antiretroviral therapy (ART) in the Centre and Littoral regions. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/hiv.12681
Publisher Site
http://dx.doi.org/10.1111/hiv.12681DOI Listing
January 2019
11 Reads

Identification and characterization of HIV positive Ethiopian elite controllers in both Africa and Israel.

HIV Med 2019 Jan 14;20(1):33-37. Epub 2018 Oct 14.

Mekelle University College of Health Sciences, Mekelle, Tigray, Ethiopia.

Objectives: HIV elite controllers (ECs) are a unique subgroup of HIV-positive patients who are long-term virologically suppressed in the absence of antiretroviral treatment (ART). The prevalence of this subgroup is estimated to be < 1%. Various cohorts of ECs have been described in developed countries, most of which have been demographically heterogeneous. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/hiv.12680
Publisher Site
http://dx.doi.org/10.1111/hiv.12680DOI Listing
January 2019
5 Reads

Management of Renal Disease: utility of a joint HIV-renal clinic.

HIV Med 2019 Feb 14;20(2):e5. Epub 2018 Oct 14.

Brighton & Sussex University Hospitals NHS Trust, Brighton, UK.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/hiv.12684
Publisher Site
http://dx.doi.org/10.1111/hiv.12684DOI Listing
February 2019
3 Reads